While hyperglycemia is a known pharmacodynamic effect of AKT inhibition and often seen as asymptomatic change to blood glucose, oral hypoglycemic drugs are indicated in the clinical management of hyperglycemia AE grade ≥ 2. The gene discussed is AKT1; the disease is Hyperglycemia.